- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 14.08. | Silexion Therapeutics GAAP EPS of -$5.17 | 1 | Seeking Alpha | ||
| 14.08. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.08. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | 728 | GlobeNewswire (Europe) | Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center... ► Artikel lesen | |
| 12.08. | Silexion Therapeutics prices $2.5M public offering | 2 | Seeking Alpha | ||
| 12.08. | Silexion Therapeutics prices $2.5M public offering at $0.65 | 1 | Investing.com | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.08. | Silexion Therapeutics, Inc.: Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering | 4 | GlobeNewswire (USA) | ||
| 10.08. | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 10.08. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 04.08. | Silexion präsentiert präklinische Daten zu Krebsmedikament SIL-204 auf Symposium für GI-Tumoren | 2 | Investing.com Deutsch | ||
| 04.08. | Silexion to present preclinical data on SIL-204 at GI cancer event | 1 | Investing.com | ||
| 04.08. | Silexion Therapeutics Corp: Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers | 410 | GlobeNewswire (Europe) | New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune "death receptor," and statistically significant downregulation of HLA-G... ► Artikel lesen | |
| 29.07. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 23.06. | Silexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | 459 | GlobeNewswire (Europe) | CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion... ► Artikel lesen | |
| 16.06. | Silexion Therapeutics Corp: Silexion Therapeutics to Attend BIO International Convention 2026 | 1 | GlobeNewswire (USA) | ||
| 28.05. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 14 | SEC Filings | ||
| 26.05. | Silexion Therapeutics announces 1-for-10 reverse share split | 1 | Seeking Alpha | ||
| 26.05. | Silexion announces 1-for-10 reverse stock split effective Thursday | 1 | Investing.com |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,70 | +0,28 % | BioNTech-Aktie: Septembertermin rückt in den Mittelpunkt | Für die BioNTech-Aktie rückt der Septembertermin in den Mittelpunkt: Auf einem internationalen Lungenkrebs-Kongress will der Mainzer Konzern erstmals globale Daten zur Kombination von Pumitamig und... ► Artikel lesen | |
| AMGEN | 379,05 | -0,76 % | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| NOVAVAX | 8,890 | 0,00 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 192,66 | -0,19 % | Biogen Inc.: Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) | -4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,350 | +0,34 % | 3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong | ||
| INTELLIA THERAPEUTICS | 11,100 | +1,83 % | Cathie Wood's ARK buys Intellia stock, sells Brera holdings | ||
| TEMPUS AI | 56,35 | +1,39 % | Tempus AI bleibt spannend - Analysten setzen Ziel bei 80 Dollar | ||
| BIOCRYST PHARMACEUTICALS | 8,598 | -0,76 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 57,60 | +0,84 % | Ascendis Pharma: Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (Navepegritide) | COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with... ► Artikel lesen | |
| EXELIXIS | 51,19 | +0,65 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| SAREPTA THERAPEUTICS | 19,360 | -2,12 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,836 | -0,97 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,091 | -2,07 % | PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology | European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart's Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS:•... ► Artikel lesen | |
| ATAIBECKLEY | 6,250 | -1,57 % | AtaiBeckley Inc. - 8-K, Current Report |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (-0,03 %) liegt der Kurs bei 0,352 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.